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Low fetuin-A levels are associated with cardiovascular death:
Impact of variations in the gene encoding fetuin.
Background. Vascular calcification is common among end-
stage renal disease (ESRD) patients and a central character-
istic of the atherosclerotic cardiovascular disease observed in
dialysis patients. Fetuin-A, a circulating calcium-regulatory gly-
coprotein that inhibits vascular calcification, is associated with
inflammation and outcome in dialysis patients. In the present
study, we evaluated the association between fetuin-A, clinical
phenotype, and outcome, as well as the impact of fetuin gene
(AHSG) polymorphisms on the protein product and outcome.
Methods. In a cohort of 258 (161 males) ESRD patients start-
ing renal replacement therapy [glomerular filtration rate (GFR)
6.8 ± 0.2 mL/min] aged 52 ± 1 years the following parame-
ters were studied: presence of malnutrition (subjective global
assessment), comorbidity [diabetes mellitus and clinical mani-
fest cardiovascular disease (CVD)], carotid plaques (N = 101),
hs-CRP, fetuin-A, S-albumin, interleukin (IL)-6, and single nu-
cleotide polymorphisms (SNPs) in the AHSG gene (N = 215)
at amino acid positions Thr248Met (C→T), Thr256Ser (C→G),
Asp276Asn (G→A), and Arg317Cys (C→T).
Results. Both all-cause (P < 0.001) and cardiovascular (P <
0.001) mortality were associated with low fetuin-A levels in-
dependently of age, smoking, diabetes, S-albumin, CVD, and
inflammation (CRP ≥10 mg/L). Inflamed (0.199 vs. 0.247 g/L;
P < 0.01) and malnourished (0.207 vs. 0.262 g/L; P < 0.05) pa-
tients had significantly lower median fetuin-A than noninflamed
and well-nourished ESRD patients, respectively. In a logistic re-
gression model (N = 101), fetuin-A was significantly (P < 0.05)
associated with the presence of carotid plaques independently
of age, CVD, diabetes, S-albumin, gender, and inflammation.
Significant correlations were observed between fetuin-A and
both S-albumin (Rho = 0.30; P < 0.0001) and IL-6 (Rho =
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−0.21; P < 0.01). Patients with the AHSG 256Ser allele had
lower serum fetuin-A levels, and higher all-cause and cardio-
vascular mortality rate if they were inflamed.
Conclusion. The present study shows that a low fetuin-A level
is associated with malnutrition, inflammation, and atheroscle-
rosis (carotid plaques), as well as with increased cardiovascular
and all-cause mortality. Because the present study demonstrates
an effect of variations in the AHSG gene on both circulating
fetuin-A levels and outcome, this indicates that ESRD patients
with the AHSG 256Ser allele are at risk of accelerated vascular
calcification.
Premature atherosclerotic cardiovascular disease
(CVD) is a leading cause of morbidity and mortality in pa-
tients with end-stage renal disease (ESRD) [1]. Although
traditional Framingham risk factors such as hypertension,
dyslipidemia, and diabetes mellitus (DM) may account
for a large proportion of the excessive burden of CVD in
this patient population, recent studies suggest that non-
traditional risk factors, such as inflammation, oxidative
stress, and vascular calcification, may also contribute [2].
Whereas ectopic mineral calcification in the vessel wall
is not commonly observed in younger age groups in
the general population, it is extremely common among
ESRD patients and a central characteristic of the pro-
gressive atherosclerosis observed in this patient group [3,
4]. The prevalence and extent of vascular and valvular
calcification and arterial stiffness are strong predictors of
CVD and all-cause mortality in both hemodialysis (HD)
[5] and peritoneal dialysis (PD) [6] patients. It is notable
that although enhanced extraosseus calcification seems
to be related mainly to enhanced Ca × PO4 ion prod-
uct in serum and a high daily calcium intake, recent ev-
idence suggests that extraossoeus calcification in ESRD
is not only a passive degenerative process but also in-
volves active inflammation [4, 7, 8]. Notably, also other
inflamed patient groups, such as systemic lupus erythe-
matosus (SLE) patients [9], have an increased coronary
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calcification burden. There may be several reasons why
a state of chronic inflammation may promote vascular
calcification and, in particular, mediators and inhibitors,
such as leptin [10], matrix-gla protein [11], tumor necrosis
factor [12], bone morphogenetic protein [13], and osteo-
protegerin [14] may be related to a process of accelerated
vascular calcification.
Fetuin-A [also called alpha2-Heremans Schmid glyco-
protein (AHSG)] is a circulating negative acute-phase
glycoprotein [15] synthesized in adult human liver tissue
[16] that inhibits ectopic Ca × PO4 ion precipitation and
vascular calcification [17]. Because Shafer et al [18] have
demonstrated that AHSG-deficient mice develop severe
calcification of various organs, it has been suggested that
an important clinical role of fetuin-A may be as an in-
hibitor of ectopic calcification. Indeed, Ketteler et al [19]
measured fetuin-A levels in 312 prevalent HD patients
and found that patients with low fetuin-A serum levels
showed a significantly poorer survival than those with
normal or high-normal values. Thus, low fetuin-A levels
may link inflammation, accelerated atherosclerosis, and
CVD in uremic subjects and could, at least in part, ex-
plain the high prevalence of vascular calcification in this
population.
Although inflammation may be one important cause
of low circulating fetuin-A levels, other factors may also
contribute. Because it has been demonstrated that at
least four nonsynonymous polymorphisms exist in the
AHSG gene [20], genetic alterations may have an effect
on the circulating amounts of this protein. One main ob-
jective of the present study was, therefore, to study the
impact of genetic AHSG polymorphisms on circulating
fetuin-A levels and outcome. Furthermore, the associ-
ations between fetuin-A and the phenotype of ESRD
patients, in particular, the presence of inflammation,
malnutrition, and atherosclerosis (carotid plaques) were
evaluated.
METHODS
Study population
Two hundred and fifty-eight ESRD patients (161
males) with a mean age of 52 ± 1 years were evalu-
ated shortly [glomerular filtration rate (GFR) 6.8 ± 0.2
mL/min] before the beginning of renal replacement ther-
apy (RRT). Whereas the majority (N = 249) of the pa-
tients were Caucasian, three were of African and six of
East-Asian origin. The patients were enrolled in an ongo-
ing prospective study on predialysis patients, the results
of which have been published in part elsewhere [21]. The
study exclusion criteria were age >70 years, overt infec-
tious complications, and unwillingness to participate in
the study. Seventy-eight (30%) of the patients had DM.
Ninety (35%) of the patients had a clinical history of cere-
brovascular, cardiovascular, and/or peripheral vascular
disease (grouped as CVD). Of the 90 patients, 25 had
suffered from cerebrovascular disease (stroke), 55 of car-
diovascular disease (acute myocardial infarction, angina
pectoris, or patients that had undergone coronary artery
bypass surgery); 27 had a history of peripheral ischemic
atherosclerotic vascular disease, and four patients had a
history of an aortic aneurysm. Mean systolic and diastolic
blood pressures at the time of investigation were 151 ± 2
and 89 ± 1 mm Hg, respectively. Evaluation of smoking
habits revealed that 133 patients were former or current
smokers, whereas 125 were nonsmokers.
During the observation period (3.5 ± 0.2 years; range
0.1–9.0 years), 88 patients died; 61 due to complications
related to CVD (cardiovascular N = 43, cerebrovascular
N = 14, peripheral vascular disease N = 3, and aortic
aneurysm N = 1), whereas 27 patients died of noncardio-
vascular, or unknown, causes (cancer N = 7, unknown
cause N = 7, infectious complications N = 7, wasting
N = 4; fatal car accident N = 1, and refusal of treatment
N = 1). One hundred thirty-six of the patients started
PD, whereas 118 patients started HD. Four patients re-
ceived a kidney transplant before starting dialysis treat-
ment, and one patient had not yet started RRT at the time
of evaluation. One hundred and two patients received a
kidney transplant subsequent to entering the study and
were followed in the same way as those that did not re-
ceive a transplant. No significant differences in age (52
± 1 vs. 52 ± 1 years), median fetuin-A (0.237 vs. 0.222
g/L), S-albumin (32.4 ± 0.7 vs. 32.9 ± 0.5 g/L), preva-
lence of clinical CVD (35 vs. 35%), prevalence of mal-
nutrition (SGA >1) (32 vs. 36%), mean arterial blood
pressure (110 ± 2 vs. 108 ± 2 mm Hg), observation time
(3.7 ± 0.2 vs. 3.2 ± 0.2 years), or proportion of patients
undergoing renal transplantation during follow-up (41
vs. 36%) were noted between patients starting HD or
PD. Many patients were on antihypertensive medica-
tions, such as angiotensin-converting enzyme inhibitors
(N = 148), beta-blockers (N = 137), and calcium-blockers
(N = 94), as well as other commonly used drugs in ESRD,
such as phosphate and potassium-binders, diuretics, and
vitamins B, C, and D. Thirty-six patients (14%) were on
statin treatment at the time of inclusion in the study. The
median dose of erythropoietin was 4000 IU/week (range
0–21,000 IU/week). Two different control groups were
studied. The control subjects for AHSG genotyping con-
sisted of 207 unrelated Caucasians living in the Stockholm
area (62% males; mean age 40 ± 1 years), whereas the
control group for serum fetuin-A consisted of 70 healthy
subjects (staff of a hospital) from the San Diego area (17
males; mean age 49 ± 2 years) with normal renal function
(S-creatinine ranging between 0.2–1.2 mg/dL). The racial
distribution was different to the Swedish population (44
Caucasians, 21 blacks, four Asians, and one Mexican). All
sera were aliquoted and stored at lower than −20◦C. The
Ethics Committee of Karolinska Institutet approved the
Stenvinkel et al: Fetuin-A in renal disease 2385
study protocol at Karolinska University Hospital at Hud-
dinge, Stockholm, and informed consent was obtained
from all patients.
Laboratory methods
After an overnight fast, venous blood samples were
taken for analysis of serum albumin, CRP, high-sensitivity
(hs) CRP (N = 250), IL-6 (N = 255), serum cal-
cium, serum phosphate, parathyroid hormone (PTH),
and serum fetuin-A. In 131 of the patients (mean age
53 ± 1 years; 81 males), repeated measurements of fast-
ing serum fetuin-A, S-albumin, and hs-CRP (N = 67)
were performed after about 12 months of RRT (PD = 79
and HD = 52). The samples were kept frozen in −70◦C
if not analyzed immediately. GFR (corrected for body
surface area) was estimated as the mean of urea and
creatinine clearance. Serum fetuin-A levels were mea-
sured by a sandwich immunoenzymometric assay using
two polyclonal human fetuin-A specific antibodies (Epi-
tope Diagnostics, Inc., San Diego, CA, USA). Briefly, an
affinity purified human fetuin-A specific polyclonal anti-
body was coated onto the well surface of standard 96-well
microplate as solid-phase, and another affinity purified
human fetuin-A specific antibody from different animal
species was directly labeled with horseradish peroxidase
(HRP) as assay tracer. After incubation, a sandwich of
“solid-phase anti-fetuin antibody –sample fetuin-A–anti-
fetuin HRP antibody” was formed, and after a washing
step, the binding tracer antibody was detected by adding
TMB substrate for color reaction. The lowest level of
human fetuin-A in prediluted serum samples detected
by this assay is 0.025 g/L, and the assay linear measure-
ment range of human fetuin-A in prediluted serum sam-
ple is up to 7 g/L. The intra-assay variation is less than
5.5% and interassay variation less than 6.8%, depending
on the sample concentration. CRP levels were measured
using an immunonephelometric method (Tina-quant;
Boehringer-Mannheim/Hitachi, Ltd., Tokyo, Japan), hs-
CRP by nephelometry, and S-albumin by the bromcresol
purple method. Plasma IL-6 levels were measured by a
high-sensitivity photometric enzyme-linked immunosor-
bent assay (ELISA) (Boehringer Mannheim, Mannheim,
Germany). The plates were read using ELISA VER-
SAmax readerTM (Molecular Devices Corp., Sunnyvale,
CA, USA), and the data were analyzed with the Softmax-
PRO software (Molecular Devices Corp.). S-calcium,
S-phosphate, and PTH were analyzed using routine meth-
ods. Subjective global assessment (SGA) was used to ob-
tain an overall clinical estimate of malnutrition as previ-
ously described [22].
In the first 101 patients participating in this study, the
right and left carotid arteries were examined with a du-
plex scanner (Ultramark 9HDI; Advanced Technology
Laboratory, Bothwell, WA, USA) using a 5 to 10 MHz
linear array transducer. The subjects were investigated in
the supine position with the head slightly turned from the
investigator. The same trained sonographer performed
all scans. Carotid plaque was defined as a localized intima-
media thickness of more than 1 mm, and at least a 100%
increase in thickness compared with adjacent wall seg-
ments. Plaques were screened for in the common, in-
ternal, and external carotid arteries. Plaque occurrence
was scored as the absence of plaques or the presence
of unilateral and bilateral plaques (grouped together).
The intraobserver variability (coefficient of variation) for
intima-media thickness was 9% [23].
Genotyping
From a 5 mL EDTA sample of peripheral blood DNA
was extracted using QIAamp DNA kits (Qiagen, Va-
lencia, CA, USA). Samples were stored at −20◦C. Se-
quence amplification was performed by the polymerase
chain reaction (PCR) on a PTC-225 Thermocycler (MJ
Research, Inc., Cambridge, MA, USA). The PCR reac-
tion volume was 50 lL, containing 20 to 50 ng of DNA,
10 pmol of each forward and reverse primer, 0.2 mmol/L
of each dNTP, 0.3 U of DyNAzymeTM II (DNA Poly-
merase, Finnzymes, Espoo, Finland), 10 mmol/L of Tris-
HCl, 1.5 mmol/L of MgCl2, 50 mmol/L of KCl, and 0.1%
Triton X-100. PCR primers were designed using the soft-
ware Primer Designer 4 for Windows, version 4.1 (Sci-
entific and Educational Software, Cary, NC, USA), and
one primer in each primer pair was biotinylated. The
Thr248Met polymorphism was amplified using forward
primer 5′ biotin - GGCTTTTGTAAGGCAACACT-
3′ and reverse primer 5′- GCAAGAATATTCAC
GGAGCT -3′. The Thr256Ser and Asp276Asn polymor-
phisms were amplified in a single fragment using for-
ward primer 5′ biotin -TCCTTTTTCCAGCCCGTGA
-3′ and reverse primer 5′- TGCACCACTGTGCGT-
GTTTT -3′. For amplification of the Arg317Cys poly-
morphism the same PCR primers were used, but in
this case the reverse primer was biotinylated (Gen-
Bank accession no: AB038689). Sequencing primers
were placed adjacent to the single nucleotide polymor-
phisms and were 5′- CCTGTGTTTGGAACACC -3′;
5′-GGTTGGGGCTGTGAG-3′; 5′- GGACGGAGGT-
GCAT -3′ and 5′-GGCGCACTACGACC -3′ for AHSG
Thr248Met, Thr256Ser, Asp276Asn, and Arg317Cys,
respectively. All oligonucleotides were synthesized by
Thermohybaid (Ulm, Germany). The pyrosequencing
reaction was performed on a PSQ96TM Instrument from
Pyrosequencing AB (Uppsala, Sweden), as described
previously [24].
Statistical analysis
Normally distributed variables are expressed as mean
± SEM, and non-normally distributed variables as
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median and range, with P < 0.05 indicating significance.
The two-sided unpaired Student t test was used for
comparisons between two groups. Comparisons between
groups for nominal variables were made by the Fisher
exact test. Correlations were performed by linear re-
gression or Spearman rank analysis and stepwise mul-
tiple regression analysis. Survival analyses were made
with the Kaplan-Meier survival curve or the Cox pro-
portional hazards model. The Cox proportional hazards
model (the PHREG procedure in the SAS System Re-
lease 8.2, Cary, NC, USA) was used to examine the
effects of baseline and follow-up variables on the out-
come variables. The goal of the analysis was to assess
the hazard ratio (HR; analogous to risk ratio or rela-
tive risk) of the particular value compared with a ref-
erence value (HR = 1). Plots of log [−log (survival rate)]
against log (survival time) were performed to establish
the validity of the proportionality assumption. Since the
proportional-hazards model assumes a constant HR over
time, the assumption for each baseline covariate of the
Cox proportional hazards model was tested before the
final analysis by evaluating a time-covariate interaction
term. The maximum-likelihood test at P < 0.05 was con-
sidered to accept that the HR of the particular variable
depended on time. As the hazard ratio associated with age
was found to be time-dependent, this covariate was di-
chotomized (>65 years). After the dichotomization there
was no evidence that age (as a dichotomous variable)
violated the proportional hazards assumption. No ad-
justments to presented P values were made for multiple
comparisons [25]. Survival was measured from the day of
examination until death or censoring, which was made at
the end of the follow-up (December 3, 2003). No patient
was lost to follow-up. Chi-square analysis was used to test
the genotype distributions for Hardy-Weinberg equilib-
rium, and linkage disequilibrium was calculated accord-
ing to Sham[26]. The statistical analysis was performed
using statistical software SAS version 8.2 (SAS Institute,
Inc., Cary, NC, USA).
RESULTS
Median fetuin-A was significantly (P < 0.0001) lower
in 258 ESRD patients (0.225 g/L; range 0.026–0.926 g/L)
compared to 70 healthy controls (0.549 g/L; range 0.350–
0.950 g/L). Demographic and clinical data of the ESRD
population with regard to clinically manifest CVD are
presented in Table 1. As expected, 90 patients with clini-
cal manifest CVD were older (60 ± 1 vs. 48 ± 1 years; P <
0.0001), and more often had DM (48 vs. 21%; P < 0.0001),
malnutrition (53 vs. 24%; P < 0.0001), and evidence of
inflammation (54 vs. 28%; P < 0.0001) than 168 patients
with no clinical signs of CVD. As expected, the preva-
lence of former/current smokers versus nonsmokers (68
vs. 43%) was higher in the CVD patient group. More-
over, ESRD patients with CVD also had carotid plaques
more often (92 vs. 59%; P < 0.001) than patients without
clinically manifest CVD. Whereas median IL-6 (9.5 vs.
5.0 pg/mL; P < 0.0001) and hs-CRP (13.0 vs. 4.2 mg/L;
P < 0.0001) were significantly elevated, S-albumin levels
(30.7 ± 0.7 vs. 33.8 ± 0.5 g/L; P < 0.001) were lower in the
CVD patient group. The difference in median fetuin-A
level (0.204 vs. 0.237 g/L) between CVD and non-CVD
patients did not attain full statistical significance. Seventy-
eight diabetic patients had a significantly lower median
fetuin-A (0.191 vs. 0.240 g/L; P < 0.01) than 180 non-
diabetic ESRD patients. No differences in the median
fetuin-A level were noted between nonsmokers and for-
mer/current smokers (0.247 vs. 0.217 g/L), or between
males and females (0.225 vs. 0.223 g/L).
Eighty-eight malnourished (SGA ≥2) patients had sig-
nificantly lower (0.207 vs. 0.262; P < 0.05) fetuin-A levels
than 160 ESRD patients with no signs of malnutrition
(SGA 1). Seventy-two patients with carotid plaques had
significantly lower median fetuin-A (0.219 vs. 0.321 g/L;
P < 0.001) and S-albumin (32.4 ± 0.8 vs. 35.9 ± 1.0 g/L; P
< 0.05) levels than 29 patients with no carotid plaques
(Fig. 1). In a logistic multiple regression model (total
R2 0.47) including age (≥median 54 years), gender, DM,
CVD, evidence of inflammation (CRP ≥10 mg/L), low
albumin levels (≤33 g/L), and fetuin-A (quartiles) only
age (OR 40.7; 95% CI 4.4–378.2; P < 0.001) and fetuin-
A (OR 2.2; 95% CI 1.1–4.0; P < 0.05) were significantly
associated with the presence of carotid plaques.
Ninety-one patients with signs of inflammation (CRP
≥10 mg/L) had significantly (P < 0.01) lower median
(0.199 vs. 0.247 g/L) fetuin-A than 167 patients with CRP
<10 mg/L. Thirty-five patients with CRP ≥10 mg/L with
no signs of malnutrition (SGA 1) had a median fetuin-A
(0.215 vs. 0.197 g/L) not significantly different from 51 pa-
tients with CRP ≥10 mg/L and malnutrition (SGA >1).
Significant correlations were observed between fetuin-A
and both age (Rho = −0.22; P < 0.001) and S-albumin
(Rho = 0.30; P < 0.0001) (Fig. 2). Significant negative
correlations were observed between fetuin-A and both
IL-6 (Rho = −0.21; P < 0.01) and hs-CRP (Rho = −0.14;
P < 0.05). No significant correlation (Rho = 0.10) was
observed between GFR and fetuin-A in 225 of the pa-
tients. A stepwise (forward) multiple regression model
analysis, correcting for the impact of age, gender, DM,
and S-albumin revealed independent (point estimates ±
SE) relationships (total R2 0.11) only between age (0.08
± 0.03; P < 0.05) and S-albumin (−0.14 ± 0.03; P < 0.001)
and fetuin-A levels (log-transformed).
Median fetuin-A level decreased significantly (P <
0.001) from 0.222 g/L (range 0.026–0.876 g/L) to 0.198
g/L (range 0.065–0.458 g/L) during 12 months of RRT.
No significant difference in change () of fetuin-A lev-
els was observed between 79 patients treated by PD
(−0.069 ± 0.019 g/L) and 52 patients treated by HD
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Table 1. Clinical characteristics of 258 incident end-stage renal disease patients with or without clinical evidence of cardiovascular disease
No CVD CVD Significance
Number 168 90
Age years 48 ± 1 60 ± 1 <0.0001
Males 59% 69% NS
Smokers (former and current) 43% 68% <0.0001
Diabetes mellitus 21% 48% <0.0001
Malnutrition (SGA >1)a 24% 53% <0.0001
Inflammation (CRP ≥10 mg/L) 28% 54% <0.0001
Carotid plaquesb 59% 92% <0.001
Body mass index kg/m2 24.3 ± 0.4 25.1 ± 0.5 NS
S-calcium mmol/L 2.53 ± 0.02 2.56 ± 0.03 NS
S-phosphate mmol/L 1.96 ± 0.05 1.79 ± 0.07 <0.05
Parathyroid hormone ng/L 286 ± 23 281 ± 41 NS
hs-CRP mg/Lc,e 4.2 (0.2–105.0) 13.0 (0.3–218.0) <0.0001
Interleukin-6 pg/mLd,e 5.0 (0.8–46.5) 9.5 (1.4–112.0) <0.0001
S-albumin g/L 33.8 ± 0.5 30.7 ± 0.7 <0.001
Fetuin-A g/Le 0.237 (0.026–0.926) 0.204 (0.046–0.758) NS
SGA, subjective global assessment; CRP, C-reactive protein.
aN = 248; bN = 101; cN = 250; dN = 255; emedian and range.
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Fig. 1. Box plots showing serum albumin (A) and fetuin-A (B) levels
in 101 ESRD patients with and without carotid plaques.
(−0.071±0.024 g/L). No significant correlations were ob-
served between  fetuin-A and either S-albumin (Rho
= 0.12) or hs-CRP (Rho = −0.19) during 12 months of
RRT.
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Fig. 2. The correlation (Rho = 0.30; P < 0.0001) between fetuin-A
and serum albumin in 258 ESRD patients.
By using Kaplan-Meier survival curves we assessed
the association between fetuin-A concentrations, divided
into quartiles with respect to low (0.026–0.153 g/L; N =
65), medium low (0.154–0.224 g/L; N = 64), medium high
(0.225–0.362 g/L; N = 64), and high (0.363–0.928 g/L;
N = 65) serum concentrations, and noted significantly
increased all-cause (log-rank 34.2; P < 0.0001) and CVD
(log-rank 23.4; P < 0.0001) mortality in patients with
low amounts of fetuin-A (Fig. 3). When patients were
divided according to median fetuin-A (≥0.225 g/L), the
adjustment for potential confounding factors (age, gen-
der, DM, S-albumin, inflammation, CVD, and smoking)
using Cox proportional hazards model revealed a signif-
icant (likelihood ratio 118.1; P < 0.0001) difference in
survival between the two groups (Fig. 4). The Cox pro-
portional hazard model was used to adjust both all-cause
and cardiovascular mortality for age (≥65 years), gen-
der, DM, CVD, smoking habits (former/current smokers
vs. nonsmokers), mode of RRT (PD vs. HD), Ca × PO4
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Fig. 3. Kaplan-Meier curves showing differences in all-cause (log-rank
34.2; P < 0.0001) (A) and cardiovascular (log-rank 23.4; P < 0.0001)
(B) mortality in 258 ESRD patients starting renal replacement therapy
according to basal serum fetuin-A levels (quartiles).
ion product (≥median), hypoalbuminemia (≤33 g/L), in-
flammation (CRP ≥10 mg/L), and fetuin-A (quartiles).
By univariate analysis all variables, except gender, mode
of RRT, and Ca × PO4 ion product, were significantly as-
sociated with both all-cause and CVD mortality as shown
in Table 2. When we did a multivariate Cox regression
analysis including variables that were significant in the
univariate analysis, fetuin-A quartiles remained signifi-
cantly associated to both all-cause (P < 0.001) and CVD
mortality (P < 0.001), whereas both CRP and S-albumin
lost their association to outcome (Table 2). If fetuin-A
was not included in the model, the association between
hypoalbuminemia (≤33 g/L) and all-cause mortality was
significant (RR 1.67; CI 1.03–2.71; P < 0.05) even after
correction for CVD, DM, inflammation, and age. We also
tested the impact of transplantation as a time-dependent
variable, but it did not influence either all-cause or CVD
mortality in the Cox regression model.
The distribution of the AHSG Thr248Met (C→T),
Thr256Ser (C→G), Asp276Asn (G→A), and Arg317Cys
(C→T) genotypes was investigated in 215 of the patients.
No differences in the genotype distribution of the four
AHSG SNPs were noted between the ESRD patients and
the 209 controls (data not shown). The genotype distri-
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Fig. 4. Kaplan-Meier curves showing unadjusted (log-rank 19.6;
P < 0.0001) (A) and adjusted (likelihood ratio 118.1 P < 0.0001) all-
cause mortality (B) in 258 ESRD patients according to median fetuin-A
levels.
bution for the Thr248Met and the Thr256Ser genotypes
were in total linkage disequilibrium (LD) (D′≥0.999)
in both patients and controls. Thus, in the following,
only data for the Thr256Ser polymorphism are given.
Since all patients tested for the Asp276Asn polymor-
phism were Asp/Asp homozygotes, no further analy-
ses were done for this variation. No significant differ-
ences in the distribution between males versus females,
patients with and without signs of inflammation, CVD
versus non-CVD, and DM versus non-DM were noted
for the Thr256Ser and Arg317Cys variations. However,
the AHSG Thr256Ser polymorphism was associated with
marked differences (Thr/Thr 0.276 g/L, Thr/Ser 0.217 g/L;
Ser/Ser 0.151 g/L; P < 0.0001) in median fetuin-A lev-
els. A stepwise (forward followed by backward) multiple
regression model analysis (N = 215), correcting for the
impact of age, gender, DM, and S-albumin, revealed in-
dependent (point estimate ± SE) relationships (total R2
0.17) between the Thr256Ser polymorphism (0.09 ± 0.03;
P < 0.01), S-albumin (−0.15 ± 0.04; P < 0.001), DM (0.09
± 0.04; P < 0.05), age (0.07 ± 0.03; P = 0.05), and fetuin-A
levels (log-transformed). When patients were divided ac-
cording to the presence of inflammation or not, both unin-
flamed (P < 0.001) and inflamed (P < 0.05) patients with
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Table 2. Unadjusted and adjusted hazard ratios for all-cause and cardiovascular mortality in patients starting renal replacement therapy
All-cause mortality Unadjusted relative
Variable risk (95% CI) P value Adjusted relative risk (95% CI) P value
Cardiovascular disease 5.49 (3.53–8.55) <0.001 3.36 (2.09–5.41) <0.001
Fetuin-A (low vs. high) 3.23 (2.10–4.95) <0.001 2.58 (1.64–4.07) <0.001
Age (≥65 years) 4.54 (2.94–7.00) <0.001 2.54 (1.56–4.14) <0.001
Diabetes mellitus 2.66 (1.75–4.05) <0.001 1.75 (1.13–2.72) <0.05
Inflammation (CRP ≥10 mg/L) 3.05 (2.00–4.67) <0.001 1.52 (0.96–2.43) NS
S-albumin (≤33 g/L) 2.61 (1.65–4.13) <0.001 1.32 (0.80–2.20) NS
Smoking (former/current vs. no smoking) 1.78 (1.16–2.73) <0.01 1.45 (0.92–2.30) NS
High Ca × PO4 product (>median) 1.38 (0.82–2.31) NS – –
Mode of RRT (PD vs. HD)a 1.09 (0.71–1.67) NS – –
Male gender 1.30 (0.83–2.02) NS – –
Cardiovascular mortality
Variable Unadjusted relative P value Adjusted relative P value
risk (95% CI) risk (95% CI)
Cardiovascular disease 7.87 (4.46–13.89) <0.001 4.87 (2.66–8.92) <0.001
Fetuin-A (low vs. high) 3.18 (1.89–5.35) <0.001 2.63 (1.51–4.59) <0.001
Diabetes mellitus 3.75 (2.26–6.21) <0.001 2.47 (1.45–4.20) <0.001
Age (≥65 years) 4.11 (2.46–6.86) <0.001 2.23 (1.26–3.95) <0.01
Inflammation (CRP ≥10 mg/L) 3.13 (1.88–5.21) <0.001 1.57 (0.90–2.73) NS
S-albumin (≤33 g/L) 2.21 (1.29–3.77) <0.01 1.11 (0.61–2.01) NS
Smoking (former/current vs. no smoking) 1.77 (1.06–2.96) <0.05 1.26 (0.73–2.19) NS
High Ca × PO4 product (>median) 1.31 (0.71–2.40) NS – –
Mode of RRT (PD vs. HD)a 1.19 (0.71–1.99) NS – –
Male gender 1.32 (0.77–2.25) NS – –
Abbreviations: RRT, renal replacement therapy; PD, peritoneal dialysis; HD, hemodialysis.
aN = 254.
the 256Ser/Ser genotype had significantly lower fetuin-
A levels than 100 patients with the Thr/Thr genotype
(Fig. 5). Moreover, patients with CRP ≥10 mg/L and the
256Thr/Ser genotype had significantly (P < 0.01) lower
fetuin-A levels than patients with no signs of inflamma-
tion with the same alleles. Near-significant differences in
all-cause (log rank 2.8; P = 0.09) and CVD (log rank 3.2;
P = 0.07) mortality were observed between 116 ESRD
patients carrying the 256Ser allele (Thr/Ser and Ser/Ser)
and 99 non-Ser allele-carrying patients. If patients were
further divided according to the presence of inflamma-
tion, inflamed (median hs-CRP 20 mg/L) patients carry-
ing the 256Ser allele (Thr/Ser and Ser/Ser) had a signif-
icantly higher mortality rate (P < 0.05) than inflamed
(median hs-CRP 25 mg/L) non-Ser allele (Thr/Thr) pa-
tients (Fig. 6). The difference between the two groups of
patients was even more pronounced (P < 0.01) after two
years of RRT (Fig. 6).
DISCUSSION
The present study confirms that low serum fetuin-A
levels are found in ESRD patients, and that a reduction
of this liver-derived glycoprotein is associated with in-
flammation and predicts both all-cause and cardiovascu-
lar mortality in ESRD patients [19]. Our data extend the
previous findings by Ketteler et al [19] and show that even
after adjustments for traditional and nontraditional risk
factors, low s-fetuin-A is associated with poor outcome
(Fig. 4). Thus, measurement of circulating fetuin-A may,
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Fig. 5. Box plot showing serum fetuin-A levels in 215 ESRD patients
according to the AHSG Thr256Ser polymorphism and evidence of in-
flammation (CRP ≥10 mg/L).
in ESRD patients, add valuable prognostic information.
Although it has repeatedly been shown that low albumin
levels are associated with both mortality [27] and car-
diac disease [28, 29] in ESRD patients, the reasons for
this association has not been established. In the present
study we found that the significant association between
S-albumin and mortality was lost when fetuin-A was
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Fig. 6. Kaplan-Meier curve showing differ-
ences (log-rank 27.6, P < 0.0001) in all-cause
mortality in ESRD patients divided into four
groups according to the presence (CRP ≥10
mg/L) or absence of inflammation and the
presence or absence of the amino acid serine
at position 256.
introduced into the Cox model. Thus, our results suggest
that the well-documented association between S-albumin
and vascular disease may be explained, at least in part,
by fetuin-A deficiency promoting vascular calcification
(Fig. 2).
One aim of the present study was to evaluate the re-
lationships between circulating fetuin-A levels and the
phenotype of ESRD patients. Our results show a signif-
icantly lower median fetuin-A level in ESRD patients
with evidence of inflammation, which confirms previous
findings [19]. In addition, we found a significant inverse
association between fetuin-A and both IL-6 and hs-CRP,
showing that fetuin-A acts as a negative acute-phase reac-
tant [15]. It has been reported that interleukin-1b down-
regulates the fetuin-A hepatic mRNA level [30]. More-
over, in LPS-challenged mice hepatic fetuin-A mRNA
is markedly down-regulated [31]. As fetuin-A may have
important functions in inflammation, such as limitation
of cytokine production by macrophages [32] and pro-
tection against TNF [33], further studies are needed to
investigate the role of fetuin-A in the inflamed ESRD
patient. The present data also demonstrate a lower me-
dian fetuin-A level in malnourished ESRD patients—a
finding not surprising in view of the strong associations
between inflammation and malnutrition (i.e., wasting) in
ESRD [21]. Indeed, a study by Wang et al [7] demon-
strated an association of inflammation and malnutrition
with cardiac valve calcification in PD patients. Whether
poor nutritional intake per se may affect fetuin produc-
tion in the liver remains to be determined. However, as
we found no significant difference in median fetuin-A
levels comparing ESRD patients with CRP ≥10 mg/L
with and without signs of malnutrition, respectively, we
find it likely that an inflammatory reaction is the ma-
jor cause of low fetuin-A levels also in malnourished
patients. The present study also showed an association
between low fetuin-A levels and the presence of carotid
plaques, independent of established risk factors, such as
age, CVD, DM, S-albumin, and inflammation. This find-
ing supports preliminary data by Moe et al [abstract; Moe
et al, J Am Soc Nephrol 14:692A, 2003], who found a cor-
relation between electron beam computer tomography
(EBCT) coronary calcifications and low fetuin-A levels
in 77 ESRD patients. Although it is well established that
medial vascular calcification is a common cell-mediated
process that predicts cardiovascular mortality in DM, the
pathogenesis of this phenomenon is not well understood
[34]. Clearly, as we found significantly lower fetuin-A lev-
els in diabetic ESRD patients compared to nondiabetic
ESRD patients, further studies should be done to clarify
the role of this circulating calcification inhibitor in the
accelerated calcification process observed in this patient
group.
In the prospective part of the study we found that 12
months of RRT was associated with a small, but signif-
icant, reduction of serum fetuin-A levels. This finding
may indirectly support the suggestion that the process of
vascular calcification is accelerated by dialysis treatment
[35]. Indeed, whereas Spiegel et al [36] have reported that
coronary and aortic calcification was not a very common
phenomenon in patients new to HD, Ketteler et al [19] re-
ported higher coronary calcification scores in patients on
long-term dialysis compared to short-term dialysis. More-
over, Moe et al [37] demonstrated that duration of dialy-
sis (vintage) and age were the only factors that correlated
with coronary calcification. Thus, it is tempting to specu-
late that decreasing fetuin-A levels during RRT may be
one reason for accelerated vascular calcification. As nei-
ther mode of dialysis therapy nor changes in S-albumin or
CRP levels were associated with the decline in fetuin-A
levels, further studies are needed to investigate if other
factors, such as changes in residual renal function, acid-
base balance, or nutritional changes may cause a decline
of fetuin-A levels during RRT.
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A novel finding of the present study was the impact
of genetic variations of the AHSG gene on circulating
fetuin-A levels in ESRD patients. The patients carrying
the 256Ser allele had lower fetuin-A levels than 256Thr
allele carriers (Fig. 5). It is notable that the presence of
inflammation had an inhibitory effect on fetuin-A levels
in patients carrying the 256Thr allele. Considering the pu-
tative proatherogenic effects of low circulating fetuin-A
levels in ESRD patients, it could be hypothesized that a
patient with a genetic propensity for low fetuin-A levels
(i.e., patients carrying the AHSG 256Ser allele) would
have a higher risk for cardiovascular premature death if
they are subjected to a chronic inflammatory process. In-
deed, as 256Ser allele carriers with signs of inflammation
had a higher mortality (especially at 2 years of follow-
up) than non-256Ser carriers with signs of inflammation,
this polymorphism seems to enhance the mortality risk
associated with inflammation (Fig. 6). Our finding sug-
gests a significant gene-environment interaction, where
the involvement of inflammatory processes may further
enhance the negative effects of low circulating fetuin-A
levels. A number of recent studies have highlighted the
importance of exposure to environmental influences for
the pathogenesis of complex disorders, such as insulin re-
sistance, DM, and CVD [38, 39], where the expression
of the final phenotype(s) may depend on complex gene-
environment interactions [40]. Clearly, additional studies
are needed to evaluate if AHSG 256Ser allele carriers
are a group of ESRD patients particularly prone to de-
velop vascular calcification during dialysis treatment, and
would benefit from different therapeutic strategies and
targets
Several limitations of the present study should be con-
sidered. First, no evaluation of coronary calcification
score (using EBCT or spiral CT) was performed. Instead,
we used carotid plaques as a surrogate marker of coro-
nary atherosclerosis and calcification. However, carotid
ultrasonography has been shown to be a useful diagnos-
tic method of coronary heart disease in a high prevalence
population [23]. Moreover, a recent study has demon-
strated that carotid plaque scores were strongly corre-
lated with coronary artery calcification scores calculated
by EBCT in 79 HD patients [41]. As carotid duplex sonog-
raphy was available only in a subset (N = 101) of the
patients, a larger patient group is needed to confirm the
relationship between fetuin-A and this surrogate marker
of coronary heart disease. However, in the present study
no differences in either age, fetuin-A, S-albumin, preva-
lence of inflammation, or Ca × PO4 were noted between
the patients in whom the presence of carotid plaques was
evaluated and the 157 patients in whom it was not (data
not shown). Second, as the association between clinically
manifest CVD and median fetuin-A level was of only bor-
derline significance, this may support the notion that the
use of a clinical definition of CVD, as used in many previ-
ous clinical studies, may be inappropriate in defining the
true prevalence of vascular disease in ESRD patients [2].
Third, only one basal determination of hs-CRP, fetuin-
A, and IL-6 was used in the present study, which may
be problematic since inflammatory biomarkers vary with
time [42]. Fourth, the racial and gender distribution dif-
fered between ESRD patients and controls; two putative
factors that could have influenced the observed differ-
ence in fetuin-A levels. Finally, the circulating serum lev-
els of fetuin-A are lower in this study compared to the
serum levels previously reported [19]. Although differ-
ences in the study population may partly contribute to
the observed difference, it should be noted that whereas
Ketteler et al [19] used a radioimmunoassay for measur-
ing human fetuin-A (which has only one raw antiserum
and thus may have some cross reaction to other serum
proteins, such as alpha-1 antichymotrypsin), we used a
new fetuin assay using two specific antibodies for fetuin
and a sandwich assay method, which is more sensitive and
specific.
CONCLUSION
The present study shows that a low level of fetuin-A is
a robust inflammation and malnutrition-related mortal-
ity risk factor in ESRD patients receiving RRT. As pa-
tients with carotid plaques had a markedly lower fetuin-A
level, this supports the hypothesis that low fetuin-A may
promote a process of accelerated atherosclerosis and vas-
cular calcification. The present study also demonstrates
that the genetic AHSG Thr256Ser variation has a ma-
jor impact on circulating serum fetuin-A levels and out-
come, especially in patients with evidence of inflamma-
tion. Clearly, if this finding can be confirmed in another
cohort, prospective studies are needed to elucidate if
chronically inflamed ESRD patients carrying the AHSG
256Ser allele are particularly prone to develop acceler-
ated vascular calcification during RRT.
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